Rafferty Asset Management
VRDN icon

Rafferty Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Rafferty Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Sell
108,749
-33,228
-23% -$535K ﹤0.01% 642
2026
Q1 		$2.78M Buy
141,977
+42,227
+42% +$1.25M 0.01% 534
2025
Q4 		$3.1M Buy
99,750
+31,685
+47% +$869K 0.01% 551
2025
Q3 		$1.47M Sell
68,065
-8,347
-11% -$151K ﹤0.01% 716
2025
Q2 		$1.07M Sell
76,412
-29,462
-28% -$400K ﹤0.01% 753
2025
Q1 		$1.43M Sell
105,874
-67,086
-39% -$1.14M 0.01% 663
2024
Q4 		$3.32M Buy
172,960
+82,309
+91% +$1.79M 0.01% 501
2024
Q3 		$2.06M Sell
90,651
-54,324
-37% -$888K 0.01% 628
2024
Q2 		$1.89M Sell
144,975
-263,912
-65% -$3.65M 0.01% 660
2024
Q1 		$7.16M Buy
408,887
+206,396
+102% +$4M 0.03% 375
2023
Q4 		$4.41M Sell
202,491
-59,805
-23% -$944K 0.02% 473
2023
Q3 		$4.02M Buy
262,296
+18,282
+7% +$349K 0.02% 445
2023
Q2 		$5.81M Buy
244,014
+67,088
+38% +$1.72M 0.03% 378
2023
Q1 		$4.5M Buy
176,926
+59,913
+51% +$1.92M 0.03% 406
2022
Q4 		$3.42M Buy
117,013
+59,222
+102% +$1.36M 0.03% 455
2022
Q3 		$1.19M Buy
+57,791
New +$1.04M 0.01% 621

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rafferty Asset Management's VRDN Position: Q2 2026 in Review

Rafferty Asset Management reduced its Viridian Therapeutics (VRDN) stake by 23% in Q2 2026, selling an estimated $535K and leaving 108,749 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #642.

Rafferty Asset Management first reported a position in VRDN in Q3 2022 and has held it in 16 quarters since. The position peaked at $7.16M in Q1 2024. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Rafferty Asset Management held 108,749 shares of Viridian Therapeutics worth $2M as of Q2 2026.
  • Rafferty Asset Management sold 33,228 Viridian Therapeutics shares in Q2 2026, an estimated $535K.
  • Viridian Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #642 holding.
  • Rafferty Asset Management first reported a position in Viridian Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Rafferty Asset Management's Viridian Therapeutics position peaked at $7.16M in Q1 2024.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.